AstraZeneca Shelves Symbicort Launch Until 2007 To Prolong Product Life
Executive Summary
AstraZeneca is delaying the launch of its asthma therapy Symbicort (budesonide/formoterol) until mid-2007 as it works to develop a longer shelf life for the product, the company said
You may also be interested in...
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
AstraZeneca Clinical Setbacks Add To Pipeline Woes
AstraZeneca is terminating development of two Phase III clinical trial programs after they failed to meet their primary endpoints, dealing a blow to the U.K. drug maker's already troubled pipeline